An experimental study on intracerebroventricular transplantation of human amniotic epithelial cells in a rat model of Parkinson's disease

Neurological Research

Volumn 32, Issue 10, 2010, Pages 1054-1059

  Yang, Xinxin ^a   Song, Lu ^a   Wu, Na ^a   Liu, Zhenguo ^a   Xue, Shouru ^b   Hui, Guozhen ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Dopamine; Human amniotic epithelial cells; Parkinson's disease; Transplantation

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID;

AMNIOTIC EPITHELIAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; COGNITION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GRAFT SURVIVAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NONHUMAN; PARKINSON DISEASE; RAT;

AMNION; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CEREBRAL VENTRICLES; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; GRAFT SURVIVAL; HUMANS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION;

EID: 77958155630     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164110X12681290831207     Document Type: Article

References (32)

1. Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs. 2001;2: 657-62.
2. Fulceri F, Biagioni F, Ferrucci M, Lazzeri G, Bartalucci A, Galli V, et al. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res. 2007;1135: 219-29.
3. Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinso-nian mice. J Neurosci. 2006;26: 13548-55.
4. Fox SH, Chuang R, Brotchie JM. Parkinson's disease\-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog Brain Res. 2008;172: 479-94.
5. Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA. The 'motor complication syndrome' in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res. 2007;177: 150-9.
6. Khanna A, Swistowska AM, Rao MS, Zeng X. Generation and transplantation of dopaminergic neurons derived from embryonic stem cells. Curr Stem Cell Res Ther. 2007;2: 139-47.
7. O'Keeffe FE, Scott SA, Tyers P, O'Keeffe GW, Dalley JW, Zufferey R, et al. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain. 2008;131: 630-41.
8. Bouchez G, Sensebé L, Vourc'h P, Garreau L, Bodard S, Rico A, et al. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int. 2008;52: 1332-42.
9. Kakishita K, Elwan MA, Nakao N, Itakura T, Sakuragawa N. Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of Parkinson's disease: a potential source of donor for transplantation therapy. Exp Neurol. 2000;165: 27-34.
10. Adinolfi M, Akle CA, McColl I, Fensom AH, Tansley L, Connolly P, et al. Expression of HLA antigens, beta 2-microglobulin and enzymes by human amniotic epithelial cells. Nature. 1982;295: 325-7.
11. Pelton R, Dickinson WME, Moses HL, Hogan BL. In situ hybridization of analysis of TGFb3 RNA expression during mouse development: comparative studies with TGFb1 and b2. Development. 1990;110: 609-20.
12. Hill DJ, Clemmons DR, Riley SC, Bassett N, Challis JR. Immunohistochemical localization of insulin-like growth factors (IGFs) and IGF binding proteins-1,-2,-3 in human placenta and fetal membranes. Placenta. 1993;14: 1-12.
13. Uchida S, Inanaga Y, Kobayashi M, Hurukawa S, Araie M, Sakuragawa N. Neurotrophie function of conditioned medium from human amniotic epithelial cells. Neurosci Res. 2000;62: 585-90.
14. Tamagawa T, Oi S, Ishiwata I, Ishikawa H, Nakamura Y. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro. Hum Cell. 2007;20: 77-84.
15. Tahara M, TasakaK, Masumoto N. Adachi K, Adachi H, Ikebuchi Y, et al. Expression of messenger ribonucleiec acid for epidermal growth factor (EGF), transforming growth factor-alpha (TGF alpha), and EGF receptor in human amnion cells: possible role of TGF alpha in prostaglandin E2 synthesis and cell proliferation. Clin Endocrinol Metab. 1995;80: 138-46.
16. Dluzen DE, Mcdermott JL, Anderson LI, Kucera J, Joyce JN, Osredkar T, et al. Age-related changes in nigrostriatal dopaminergic function are accentuated in z/2 brain-derived neurotrophic factor mice. Neumscience. 2004;128: 201-8.
17. Enosawa S, Sakuragawa N, Suzuki S. Possible use of amniotic cells for regenerative medicine. Nippon Rinsho. 2003;61: 396-400.
18. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008;15: 88-99.
19. Sakuragawa N, Thangavel R, Mizuguchi M, Hirasawa M, Kamo I. Expression of markers for both neuronal and glial cells in human amniotic epithelial cells. Neurosci Lett. 1996;209: 9-12.
20. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic Press; 1998.
21. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci. 2002;15: 120-32.
22. Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B, et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci. 2008;28: 4311-6.
23. Toriumi H, Yoshikawa M, Matsuda R, Nishimura F, Yamada S, Hirabayashi H, et al. Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement. Neurol Res. 2009;31: 220-7.
24. Muramatsu S, Okuno T, Suzuki Y, Nakayama T, Kakiuchi T, Takino N, et al. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. Synapse. 2009;63: 541-8.
25. Cho MS, Hwang DY, Kim DW. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale. Nat Protoc. 2008;3: 1888-94.
26. Bilic G, Zeisberger SM, Mallik AS, Zimmermann R, Zisch AH. Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy. Cell Transplant. 2008;17: 955-68.
27. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005;23: 1549-59.
28. Ishii T, Ohsugi K, Nakamura S, Sato K, Hashimoto M, Mikoshiba K, et al. Gene expression of oligodendrocyte markers in human amniotic epithelial cells using neural cell-type-specific expression system. Neurosci Lett. 1999;268: 131-4.
29. Bousquet M, Gibrat C, Saint-Pierre M, Julien C, Calon F, Cicchetti F. Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33: 1401-8.
30. Porritt MJ, Batchelor PE, Howells DW. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol. 2005;192: 226-34.
31. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson's disease. Expert Rev Neurother. 2008;8: 1125-39.
32. Bauer M, Meyer M, Grimm L, Meitinger T, Zimmer J, Gasser T, et al. Nonviral glial cell-derived neurotrophic factor gene transfer enhances survival of cultured dopaminergic neurons and improves their function after transplantation in a rat model of Parkinson's disease. Hum Gene Ther. 2000;11: 1529-41.